INHIBIKASE THERAPEUTICS, INC. 2020 EQUITY INCENTIVE PLAN STOCK OPTION GRANT NOTICE AND AWARD AGREEMENTNotice And • March 8th, 2022 • Inhibikase Therapeutics, Inc. • Biological products, (no disgnostic substances) • Delaware
Inhibikase Therapeutics, Inc., a Delaware corporation (the “Company”), pursuant to its 2020 Equity Incentive Plan (the “Plan”), hereby grants to the individual listed below (“Participant”) an option to purchase the number of Shares set forth below (the “Option”). The Option described in this Stock Option Grant Notice (the “Grant Notice”) is subject to the terms and conditions set forth in the Award Agreement attached hereto as Exhibit A (the “Agreement”) and the Plan, each of which is incorporated herein by reference. Unless otherwise defined herein, capitalized terms used in this Grant Notice and the Agreement will have the meanings defined in the Plan.
NOTICE AND ACKNOWLEDGEMENT OF MODIFICATION TO PAYMENT SCHEDULENotice And • May 15th, 2013 • Globalwise Investments Inc • Services-prepackaged software
The Director of the Department of Development of the State of Ohio, now known as the Ohio Development Services Agency (the “Director”) and Intellinetics, Inc. (the “Borrower”) entered into a Loan Agreement dated July 17, 2009 in the original principal amount of $1,012,500.00 evidenced by a Cognovit Promissory Note dated July 17, 2009 (the “Note”).
NOTICE AND OFFER OF SETTLEMENT UNDER AMENDED AND RESTATED SECURED SUBORDINATED CONVERTIBLE PROMISSORY NOTENotice And • November 10th, 2015 • Quest Solution, Inc. • Services-computer integrated systems design • California
THIS NOTICE AND OFFER OF SETTLEMENT UNDER AMENDED AND RESTATED SECURED SUBORDINATED CONVERTIBLE PROMISSORY NOTE (this “Waiver”), dated September 28, 2015 (the “Effective Date”), is entered into by and among George Zicman (the “Holder”) and Quest Solution, Inc., a Delaware corporation (the “Corporation”).
ENSYSCE BIOSCIENCES, INC. AMENDED AND RESTATED 2021 OMNIBUS INCENTIVE PLAN STOCK OPTION GRANT NOTICE AND AWARD AGREEMENTNotice And • March 31st, 2022 • Ensysce Biosciences, Inc. • Pharmaceutical preparations • Delaware
Ensysce Biosciences, Inc., a Delaware corporation (the “Company”), pursuant to its 2021 Amended and Restated Omnibus Incentive Plan (the “Plan”), hereby grants to the individual listed below (“Participant”) an option to purchase the number of shares of Common Stock (the “Shares”) set forth below (the “Option”). The Option described in this Stock Option Grant Notice (the “Grant Notice”) is subject to the terms and conditions set forth in the Award Agreement attached hereto as Exhibit A (the “Agreement”) and the Plan, each of which is incorporated herein by reference. Unless otherwise defined herein, capitalized terms used in this Grant Notice and the Agreement will have the meanings defined in the Plan.
NOTICE AND DIRECTION - DM COMPONENT AND EXPERIMENTAL PROJECTSNotice And • July 10th, 2012
This Notice and Direction is made in respect of the Financing Agreement between the CMF and the Applicant further described as follows:
COGNITION THERAPEUTICS, INC. 2021 EQUITY INCENTIVE PLAN STOCK OPTION GRANT NOTICE ANDNotice And • July 19th, 2021 • Cognition Therapeutics Inc • Biological products, (no disgnostic substances) • Delaware
Cognition Therapeutics, Inc., a Delaware corporation (the “Company”), pursuant to its 2021 Equity Incentive Plan (the “Plan”), hereby grants to the individual listed below (“Participant”) an option to purchase the number of Shares set forth below (the “Option”). The Option described in this Stock Option Grant Notice (the “Grant Notice”) is subject to the terms and conditions set forth in the Award Agreement attached hereto as Exhibit A (the “Agreement”) and the Plan, each of which is incorporated herein by reference. Unless otherwise defined herein, capitalized terms used in this Grant Notice and the Agreement will have the meanings defined in the Plan.
